* U.S. authorities recommended pause after clot cases * Belgium says won’t stop J&J shot’s rollout (adds EU spokesman) BRUSSELS, April 13 (Reuters) - The European Commission is seeking clarification from Johnson & Johnson about the company’s “completely unexpected” announcement of delays in COVID-19 vaccine deliveries to the EU, an EU official told Reuters on Tuesday. The U.S. company said it would delay rolling out the vaccine in Europe after U.S. federal health agencies recommended pausing the use of the vaccine following cases of rare blood clots in six women under 50 after they were given it. Despite the U.S. decision, Belgium said it would not stop its rollout at this stage, while the Dutch drug regulator said benefits of the J&J vaccine outweighed possible risks, and Spain said it was not aware of any delay.